Broadway Wealth Solutions Inc. Buys Shares of 1,396 IQVIA Holdings Inc. (NYSE:IQV)

Broadway Wealth Solutions Inc. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,396 shares of the medical research company’s stock, valued at approximately $274,000.

Other hedge funds also recently modified their holdings of the company. Synergy Asset Management LLC bought a new stake in IQVIA in the 4th quarter valued at $33,000. Lee Danner & Bass Inc. acquired a new stake in IQVIA during the fourth quarter worth about $44,000. Zions Bancorporation N.A. increased its stake in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 85 shares during the period. Versant Capital Management Inc raised its holdings in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of IQVIA during the 4th quarter worth approximately $60,000. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 0.3 %

Shares of NYSE IQV opened at $179.40 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $176.74 and a fifty-two week high of $253.84. The firm has a market capitalization of $31.63 billion, a P/E ratio of 23.92, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company’s 50 day simple moving average is $193.55 and its 200 day simple moving average is $206.91.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on IQV shares. Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. UBS Group lowered their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Truist Financial reaffirmed a “buy” rating and set a $263.00 price objective (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. Robert W. Baird cut their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.